GSK RSV shot 43% effective against severe disease in third year
GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...
Analysis-GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
(Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age ...
GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...
GSK rises Monday, outperforms market
Shares of GSK PLC GSK rose 1.40% to £14.80 Monday, on what proved to be an all-around favorable trading session for the stock ...